Changes in serum histologic surrogate markers and procollagen III N-terminal peptide as independent predictors of HBeAg loss in patients with chronic hepatitis B during entecavir therapy

► We assessed serum markers of liver fibrosis / inflammation during entecavir therapy. ► Most serum markers improved in patients with hepatitis B during entecavir therapy. ► Procollagen III N-terminal peptide is an independent predictor of HBeAg loss.